24/7 Market News Snapshot 28 May, 2025 – CollPlant Biotechnologies Ltd Ordinary Shares (NASDAQ:CLGN)

May 28, 2025

DENVER, Colo., 28 May, 2025 (www.247marketnews.com) – (NASDAQ:CLGN) are discussed in this article.
CollPlant Biotechnologies Ltd (CLGN) has recently reported significant advances in its financial performance and product development, marking an impressive start to the year. The company opened trading today at $2.00, experiencing a notable rise of 24.92% to a current price of $2.411. This surge, following a previous closing price of $1.93 and a trading volume of 634.66K shares, highlights strong investor confidence and robust market activity surrounding its innovative solutions in regenerative and aesthetic medicine.

In its latest quarterly report, CollPlant announced a pivotal $2 million milestone payment from AbbVie, a strategic partner in a joint venture that focuses on developing dermal and soft tissue fillers. This collaboration has moved a new dermal filler candidate into the clinical phase, where it has shown promising interim results. Yehiel Tal, the CEO of CollPlant, remarked, “Our disciplined approach in advancing core programs and cost optimization underpins our commitment to shareholders. We are highly optimistic about our regenerative breast implant program, where preclinical studies indicate remarkable outcomes, positioning us as a potential leader in the regenerative medicine field.”

The company’s regenerative breast implants, designed using proprietary recombinant human collagen (rhCollagen) technology, aim to promote tissue regeneration while utilizing biocompatible materials to minimize adverse immune reactions. Furthermore, CollPlant is set to commence clinical studies for its innovative photocurable dermal filler, having successfully completed earlier preclinical trials.

Adding to its competitive edge, CollPlant has fortified its intellectual property portfolio with a critical U.S. patent, ensuring robust protection for its product candidates. Through these strategic initiatives and expanded distribution of Vergenix™ STR for tendon injuries, CollPlant is well-positioned to drive further innovation and address significant healthcare needs in the regenerative medicine sector.

Related news for (CLGN)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.